Savara has multiple products in various stages of clinical development.
- A pivotal Phase 3 IMPALA clinical trial of Molgradex to treat patients with PAP is currently ongoing worldwide; patient enrollment is anticipated to be complete in the first quarter of 2018 and top-line results are anticipated in the fourth quarter 2018.
- A Phase 2a clinical trial of Molgradex to treat patients with antibiotic-resistant NTM lung infection in anticipated to start in early 2018.
- Savara initiated its pivotal Phase 3 AVAIL Study of AeroVanc for the treatment of MRSA in Cystic Fibrosis patients in Q3 2017.
- Aironite is currently in clinical studies for the treatment of heart failure with preserved ejection fraction (HFpEF).
Go to products